Anti-inflammatory effects of myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease

European Journal of Medical Research

Volumn 14, Issue SUPPL.4, 2009, Pages 205-209

  Rantzsch, U ^a   Vacca, G ^a   Duck R ^a   Gillissen, A ^a  

^a Robert Koch Klinik   (Germany)

Author keywords

alveolar macrophages; COPD; cytokines; essential oils; eucalyptus oil and orange oil; myrtol; reactive oxygen species

Indexed keywords

ANTIINFLAMMATORY AGENT; ESSENTIAL OIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; MYRTOL; REACTIVE OXYGEN METABOLITE; TERPENE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DRUG COMBINATIONS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-8; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; MONOTERPENES; OILS, VOLATILE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955502858     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S4-205     Document Type: Article

References (27)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Rabe KF, Hurd SS, Anzueto A, Barnes PJ, Buist SA, Calverley PMA, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Weel van C, Zielinski J, Am J Respir Crit Care Med 2007 176 532 55 10.1164/rccm.200703-456SO 17507545 (Pubitemid 47403272)
2. WHO report of an expert committee: Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysema. World Health Organization, WHO Techn Rep Ser 1961 213 14 9
3. Airway epithelial inflammatory responses and clinical paramters in COPD. Patel IS, Roberts NJ, Lloye-Owen SJ, Sapsford RJ, Wedzicha JA, Eur Respir J 2003 22 94 9 10.1183/09031936.03.00093703 12882457 (Pubitemid 36896477)
4. Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Gillissen A, Bartling A, Schoen S, Schultze-Werninghaus G, Lung 1997 175 235 42 10.1007/PL00007570 9195551 (Pubitemid 27260312)
5. Antioxidant properties of ambroxol. Nowak D, Antczak A, Krol M, Bialasiewicz P, Pietras T, Free Radic Biol Med 1994 16 517 22 10.1016/0891-5849(94)90130-9 8005537 (Pubitemid 24106000)
6. Characterization of N-acetylcyteine and ambroxol in antioxidant therapy. Gillissen A, Nowak D, Resp Med 1998 92 609 23 10.1016/S0954-6111(98)90506-6 (Pubitemid 28174829)
7. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Poole PJ, Black PN, BMJ 2001 322 1 6 10.1136/bmj.322.7277.1 11141128
8. Effect of oral N-acetylcysteine on mucus clearance. Millar AB, Pavia D, Agnew JE, Lopez-Vidriero MT, Lauque D, Clarke SW, Br J Dis Chest 1985 79 262 6 3893512 (Pubitemid 15063926)
9. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCHUS): a randomised placebo-controlled trial. Decramer M, Rutten-von-Molken MPMH, Dekhuijzen PNP, Schayck van CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A, Lancet 2005 365 1552 60 10.1016/S0140-6736(05)66456-2 15866309 (Pubitemid 40615404)
10. Global initiative for chronic obstructive lung disease. GOLD Executive Committee, 2007 http://www.goldcopd.com
11. Herbal medicines for the treatment of COPD: a systematic review. Guo X, Pittler MH, Ernst E, Eur Respir J 2006 28 330 8 10.1183/09031936.06.00119905 16880367 (Pubitemid 44914232)
12. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Matthys H, de Mey C, Carls C, Rys A, Geib A, Wittig T, Arzneim-Forsch/Drug Res 2000 50 700 11 (Pubitemid 30642803)
13. Efficacy and tolerability of myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study. Meister R, Wittig T, Beuscher N, de Mey C, Arzneim-Forsch/Drug Res 1999 1 351 8 (Pubitemid 29198115)
14. Antioxidant properties of essential oils. Possible explanations for their anti-inflammatory effects. Gramann J, Hippeli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF, Arzneim-Forsch/Drug Res 2000 50 135 9 (Pubitemid 30114842)
15. Report of the European Society of pneumology task group on BAL. Technical recommendations and guidelines for bronchalveolar lavage (BAL). Eur Respir J 1989 2 561 85 2663535
16. Report of ERS Task Force: guideline for measurement of acellular components and standardization of BAL. Haslam PL, Baughman RP, Eur Respir J 1999 14 245 8 10515395 (Pubitemid 29461283)
17. Oxidant-antioxidant balance in alveolar macrophages form newborn rats. Delacourt C, d'Ortho MP, Macquin-Mavier I, Pezet S, Housset B, Lafuma C, Harf A, Eur Respir J 1996 9 2517 24 10.1183/09031936.96.09122517 8980963 (Pubitemid 26407902)
18. Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in human mononuclear phagocytes in vitro. Juergens UR, Engelen T, Stober M, Gillissen A, Vetter H, Pulm Phamacol Therapeutics 2004 17 281 7 10.1016/j.pupt.2004.06.002 (Pubitemid 39345409)
19. Interference of Myrtol standardized with inflammatory and allergic mediators. Beuscher N, Kietzmann M, Bien E, Champeroux P, Arzneim-Forsch/Drug Res 1998 48 985 9 (Pubitemid 28496757)
20. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Aruoma OI, Halliwell B, Hoey BM, Butler J, Free Radic Biol Med 1989 6 593 7 10.1016/0891-5849(89)90066-X 2546864 (Pubitemid 19147809)
21. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Gillissen A, Jaworska M, Orth M, Coffiner M, Maes P, App EM, Cantin AM, Schultze-Werninghaus G, Resp Med 1997 91 159 68 10.1016/S0954-6111(97)90052-4 (Pubitemid 27122666)
22. N-Acetylcystein: ein funktioneller Sauerstoffrädikalfanger in vitro und ex vivo in Monozyten und neutrophilen Granulozyten bei Patienten mit einer COPD. Jaworska M, Gillissen A, Schärling B, Wickenburg D, Schultze-Werninghaus G, Pneumologie 1995 49 539 45 8584524
23. Use of N-acetylcysteine in clinical toxicology. Flanagan RJ, Meredith TJ, Am J Med 1991 3C 131S 9S
24. N-acetylcysteine in experimental and clinical acute lung injury. Bernard GR, Am J Med 1991 91 Suppl 3C 3C-54S 3C-59S
25. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Chung KF, Adcock IM, Eur Respir J 2008 31 1334 56 10.1183/09031936.00018908 18515558
26. Cells, mediators and Toll-like receptors in COPD. Sarir H, Henricks PAJ, Houwelingen AH, Nijkamp FP, Folkerts G, Eur J Pharmacol 2008 585 346 53 10.1016/j.ejphar.2008.03.009 18410916
27. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund L, Holgate ST, Davies DE, Delany DJ, Wilson SJ, Djukanovic R, Thorax 2004 59 837 42 10.1136/thx.2003.019349 15454648 (Pubitemid 39389622)